New Developments in the Understanding and Treatment of Autoimmune Hemolytic Anemia: Traditional and Novel Tests

Tristan F P McKnight; Maggie A DiGuardo; Eapen K Jacob

doi:10.1016/j.hoc.2021.11.003

New Developments in the Understanding and Treatment of Autoimmune Hemolytic Anemia: Traditional and Novel Tests

Hematol Oncol Clin North Am. 2022 Apr;36(2):293-305. doi: 10.1016/j.hoc.2021.11.003. Epub 2022 Mar 11.

Authors

Tristan F P McKnight¹, Maggie A DiGuardo¹, Eapen K Jacob²

Affiliations

¹ Division of Transfusion Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
² Division of Transfusion Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. Electronic address: Jacob.Eapen@mayo.edu.

PMID: 35282953
DOI: 10.1016/j.hoc.2021.11.003

Abstract

Careful consideration of the clinical history with traditional testing such as an antibody screen and direct antiglobulin test (DAT) allow for the categorization of most forms of autoimmune hemolytic anemia. Based on the initial findings, specialized testing can further categorize disease entities and increase the sensitivity of testing. In this section, we explain the diagnostic findings of both traditional and novel testing and how their appropriate interpretations help distinguish the forms of autoimmune hemolytic anemia (AIHA).

Keywords: AIHA; Autoimmune hemolytic anemia; DAT-Positive.

Publication types

Review

MeSH terms

Anemia, Hemolytic, Autoimmune* / diagnosis
Anemia, Hemolytic, Autoimmune* / therapy
Coombs Test
Humans